T regulatory cell
Showing 1 - 25 of >10,000
Lupus Nephritis, Type 1 Diabetes Trial in Cairo (autologous adoptive T regulatory cell transfer.)
Not yet recruiting
- Lupus Nephritis
- Type 1 Diabetes Mellitus
- autologous adoptive T regulatory cell transfer.
-
Cairo, EgyptAin shams university, faculty of medicine
Sep 30, 2022
Deficient T Regulatory Cell Function in Relapsing Remitting
Recruiting
- Relapse Remitting Multiple Sclerosis
-
Philadelphia, PennsylvaniaThomas Jefferson University
Jun 13, 2022
Epithelial Ovarian Cancer Trial in Pittsburgh (Pembrolizumab, E7777)
Not yet recruiting
- Epithelial Ovarian Cancer
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Aug 4, 2022
Islet Transplantation Trial in Palo Alto (Infusion of recipient T regulatory cell, Infusion of concomitant Donor Derived
Not yet recruiting
- Islet Transplantation
- Infusion of recipient T regulatory cell
- Infusion of concomitant Donor Derived Vertebral Bone Marrow
-
Palo Alto, CaliforniaStanford University
Jul 25, 2023
Interleukins in Periodontal Disease Progression
Recruiting
- Periodontitis
- Gingivitis
- Flow Cytometric Detection of Regulatory T Cells and Cytokines analysis by ELISA
-
Assiut, Asyut, EgyptDepartment of oral medicine, Periodontology, Oral diagnosis and
Nov 16, 2023
CKD (Chronic Kidney Disease) Stage 5D Trial (Sodium propionate, Placebo)
Not yet recruiting
- CKD (Chronic Kidney Disease) Stage 5D
- Sodium propionate
- Placebo
- (no location specified)
May 4, 2023
Kidney Failure, Kidney Transplant Trial in Boston (T Regulatory Cell Infusion)
Completed
- Kidney Failure, Kidney Transplant
- T Regulatory Cell Infusion
-
Boston, MassachusettsMassachusetts General Hospital
Nov 15, 2021
Living Donor Kidney Transplantation Trial in Palo Alto, Chicago (Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs)
Recruiting
- Living Donor Kidney Transplantation
- Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs
-
Palo Alto, California
- +1 more
May 6, 2022
COVID19, ARDS Trial in United States (CK0802, Placebo)
Completed
- COVID19
- ARDS
- CK0802
- Placebo
-
Baltimore, Maryland
- +4 more
Mar 8, 2022
Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)
Enrolling by invitation
- Kidney Transplant Rejection
- End Stage Renal Disease
- Urine sample
- +2 more
-
Leuven, Belgium
- +5 more
Aug 3, 2023
GVHD Trial in Stanford (donor regulatory T lymphocytes, laboratory biomarker analysis)
Suspended
- Graft Versus Host Disease
- donor regulatory T lymphocytes
- laboratory biomarker analysis
-
Stanford, CaliforniaStanford University Hospitals and Clinics
Aug 18, 2021
Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute
Recruiting
- Acute Rejection of Renal Transplant
- Graft Failure
- Donor-derived cell-free DNA
-
Loma Linda, CaliforniaLoma Linda University Health
Jul 19, 2022
Chronic GVHD, Hematologic and Lymphocytic Disorder, Steroid Refractory GVHD Trial in Duarte (procedure, biological, other)
Not yet recruiting
- Chronic Graft Versus Host Disease
- +2 more
- Biopsy
- +11 more
-
Duarte, CaliforniaCity of Hope Medical Center
Aug 7, 2023
Chronic GVHD Trial in Sevilla (Regulatory T-cell enriched infusion)
Recruiting
- Chronic Graft vs Host Disease
- Regulatory T-cell enriched infusion
-
Sevilla, SpainJosé Antonio Pérez Simón
May 20, 2022
Acute Respiratory Distress Syndrome, Covid19 Trial in Stanford (T regulatory cells)
Withdrawn
- Acute Respiratory Distress Syndrome
- Covid19
- T regulatory cells
-
Stanford, CaliforniaStanford University
Apr 14, 2021
Stem Cell Transplant Complications, Graft Vs Host Disease, Myeloid Leukemia, Acute Trial in Boston (radiation, drug, biological,
Recruiting
- Stem Cell Transplant Complications
- +4 more
- Radiation
- +7 more
-
Boston, MassachusettsDana Farber Cancer Institute
Jan 19, 2023
Diabetes type1 Trial (cePolytreg)
Not yet recruiting
- Diabetes type1
- cePolytreg
- (no location specified)
Jul 8, 2022
Rejection; Transplant, Liver, Liver Failure, Liver Diseases Trial in Cambridge, London (QEL-001)
Recruiting
- Rejection; Transplant, Liver
- +2 more
-
Birmingham, United Kingdom
- +3 more
Dec 22, 2022
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia Trial in United States (Orca-T,
Recruiting
- Acute Myeloid Leukemia
- +7 more
- Orca-T
- Standard-of-Care
-
Duarte, California
- +13 more
Jan 25, 2023
GVHD, Allogeneic Hematopoietic Cell Transplant Recipient Trial in Palo Alto (Regulatory T Cells)
Completed
- Graft Versus Host Disease
- Allogeneic Hematopoietic Cell Transplant Recipient
- Regulatory T Cells
-
Palo Alto, CaliforniaStanford University, School of Medicine
Sep 20, 2021
Healthy Volunteers Trial in Paris (ILT101, Placebo)
Completed
- Healthy Volunteers
- ILT101
- Placebo
-
Paris, FranceClinical Investigation Center Paris Est Hôpital Universitaire Pi
Dec 10, 2021
Myeloid Leukemia, Chronic, Acute Myelogenous Leukemia, MDS (MDS) Trial in Palo Alto (Conventional T cells (Tcon) and Regulatory
Recruiting
- Myeloid Leukemia, Chronic
- +8 more
- Conventional T cells (Tcon) and Regulatory T cells (Treg)
-
Palo Alto, CaliforniaStanford University School of Medicine Palo Alto, California, Un
Aug 18, 2021
DLBCL, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma Trial in Minneapolis (E7777)
Recruiting
- DLBCL
- +3 more
-
Minneapolis, MinnesotaUniversity of Minnesota, Masonic Cancer Center
Jul 1, 2022
Chronic GVHD Trial in Bologna (T reg DLI)
Recruiting
- Chronic Graft Versus Host Disease
- T reg DLI
-
Bologna, BO, ItalyUniversity Hospital St. Orsola-Malpighi Polyclinic
Jan 14, 2021
GVHD Trial in Hackensack (Cyclophosphamide and Sirolimus, Low dose IL-2 with Cytoxan + Sirolimus, Low dose IL-2, low dose
Terminated
- Graft Versus Host Disease
- Cyclophosphamide and Sirolimus
- +3 more
-
Hackensack, New JerseyJohn Theurer Cancer Center at Hackensack University Medical Cent
Feb 4, 2022